← Leaderboards
Joseph L Witztum
University Of California San Diego
$27,414,786
Attributed
$27,414,786
Total exposure
29
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.2M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$67,878,967 · 31
By mechanism
P01$37,887,827 · 11
P50$17,062,483 · 5
R01$6,569,476 · 5
U54$2,979,155 · 2
M01$2,215,424 · 6
T32$1,019,529 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Andrew Baird$5,563,976
- Teresa Dianne Langford$10,314,213
Others in their field
Top investigators on “Atherosclerosis”
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$63,519,256
- Josef Coresh · New York University School Of Medicine$60,445,875
- Daniel James Rader · University Of Pennsylvania$50,278,074
- Howard N Hodis · University Of Southern California$49,943,399
- Gary K Owens · University Of Virginia$42,472,259
- Alan Richard Tall · Columbia University Health Sciences$38,866,887
Research focus
AtherosclerosisOxidationMacrophageCellsAtherogenesisOxidized Low Density LipoproteinAntibodiesClinical ResearchImmuneInflammationResearch PersonnelHuman SubjectLigandsInflammatoryMolecularPlayEpitopesChronicInsightLow-Density LipoproteinsLeadLaboratoriesOxidized LipidGene Expression
Grant awards (124)
PPG Phenotyping$404,939
P01 · FY2024 · HL · contact PI
PPG Phenotyping$414,344
P01 · FY2023 · HL · contact PI
Pivotal Role of Oxidation-specific Epitopes in CVD and NASH.$368,369
P01 · FY2023 · HL · contact PI
PPG Phenotyping$413,929
P01 · FY2022 · HL · contact PI
Pivotal Role of Oxidation-specific Epitopes in CVD and NASH.$368,126
P01 · FY2022 · HL · contact PI
PPG Phenotyping$414,146
P01 · FY2021 · HL · contact PI
Pivotal Role of Oxidation-specific Epitopes in CVD and NASH.$368,382
P01 · FY2021 · HL · contact PI
PPG Phenotyping$415,844
P01 · FY2020 · HL · contact PI
Pivotal Role of Oxidation-specific Epitopes in CVD and NASH.$370,629
P01 · FY2020 · HL · contact PI
Pivotal Role of Oxidation-specific Epitopes in CVD and NASH$551,250
R01 · FY2019 · HL · contact PI
Experimental Endocrinology and Metabolism$211,073
T32 · FY2019 · DK · contact PI
Role of Immune Mechanisms in Athersclerosis and Inflammation$2,684,515
P01 · FY2018 · HL · contact PI
Role of B-1 Cells and Natural antibodies in Inflammation and Atherosclerosis$485,150
P01 · FY2018 · HL · contact PI
Analytical Core$357,727
P01 · FY2018 · HL · contact PI
Experimental Endocrinology and Metabolism$207,157
T32 · FY2018 · DK · contact PI
Administrative Core$143,037
P01 · FY2018 · HL · contact PI
Role of Immune Mechanisms in Athersclerosis and Inflammation$2,684,515
P01 · FY2017 · HL · contact PI
Role of B-1 Cells and Natural antibodies in Inflammation and Atherosclerosis$485,150
P01 · FY2017 · HL · contact PI
Analytical Core$357,727
P01 · FY2017 · HL · contact PI
Experimental Endocrinology and Metabolism$194,238
T32 · FY2017 · DK · contact PI
Administrative Core$143,037
P01 · FY2017 · HL · contact PI
Role of Immune Mechanisms in Athersclerosis and Inflammation$2,684,515
P01 · FY2016 · HL · contact PI
Role of B-1 Cells and Natural antibodies in Inflammation and Atherosclerosis$485,150
P01 · FY2016 · HL · contact PI
Analytical Core$357,727
P01 · FY2016 · HL · contact PI
Experimental Endocrinology and Metabolism$191,159
T32 · FY2016 · DK · contact PI
Administrative Core$143,037
P01 · FY2016 · HL · contact PI
Role of Immune Mechanisms in Athersclerosis and Inflammation$2,644,248
P01 · FY2015 · HL · contact PI
Role of B-1 Cells and Natural antibodies in Inflammation and Atherosclerosis$477,873
P01 · FY2015 · HL · contact PI
Analytical Core$352,360
P01 · FY2015 · HL · contact PI
Administrative Core$140,890
P01 · FY2015 · HL · contact PI
Role of Immune Mechanisms in Athersclerosis and Inflammation$2,712,015
P01 · FY2014 · HL · contact PI
Role of B-1 Cells and Natural antibodies in Inflammation and Atherosclerosis$481,536
P01 · FY2014 · HL · contact PI
Analytical Core$370,004
P01 · FY2014 · HL · contact PI
Experimental Endocrinology and Metabolism$182,772
T32 · FY2014 · DK · contact PI
Administrative Core$141,971
P01 · FY2014 · HL · contact PI
Experimental Endocrinology and Metabolism$33,130
T32 · FY2014 · DK · contact PI
Program Project: Role of Innate Immunity in Atherosclerosis$2,585,410
P01 · FY2012 · HL · contact PI
Bridge D: OXIDIZE LIPIDS IN MACROPHAGES$460,350
U54 · FY2012 · GM · contact PI
Role of Innate Immune Mechanisms in Atherogenesis$388,601
P01 · FY2012 · HL · contact PI
Administrative Core$108,808
P01 · FY2012 · HL · contact PI
Program Project: Role of Innate Immunity in Atherosclerosis$2,569,768
P01 · FY2011 · HL · contact PI
Bridge D: OXIDIZE LIPIDS IN MACROPHAGES$451,814
U54 · FY2011 · GM · contact PI
Role of Innate Immune Mechanisms in Atherogenesis$393,535
P01 · FY2011 · HL · contact PI
Development of a Vaccine Approach to Inhibit Atherosclerosis$386,250
R01 · FY2011 · HL · contact PI
Administrative Core$110,189
P01 · FY2011 · HL · contact PI
Program Project: Role of Innate Immunity in Atherosclerosis$48,470
P01 · FY2011 · HL · contact PI
Program Project: Role of Innate Immunity in Atherosclerosis$2,569,768
P01 · FY2010 · HL · contact PI
Bridge D: OXIDIZE LIPIDS IN MACROPHAGES$465,051
U54 · FY2010 · GM · contact PI
Development of a Vaccine Approach to Inhibit Atherosclerosis$442,003
R01 · FY2010 · HL · contact PI
Role of Innate Immune Mechanisms in Atherogenesis$386,250
P01 · FY2010 · HL · contact PI
Administrative Core$108,149
P01 · FY2010 · HL · contact PI
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$76,799
M01 · FY2010 · RR · contact PI
Development of a Vaccine Approach to Inhibit Atherosclerosis$6,616
R01 · FY2010 · HL · contact PI
Program Project: Role of Innate Immunity in Atherosclerosis$2,569,768
P01 · FY2009 · HL · contact PI
Bridge D: OXIDIZE LIPIDS IN MACROPHAGES$468,690
U54 · FY2009 · GM · contact PI
Role of Innate Immune Mechanisms in Atherogenesis$386,250
P01 · FY2009 · HL · contact PI
Development of a Vaccine Approach to Inhibit Atherosclerosis$386,250
R01 · FY2009 · HL · contact PI
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$206,656
M01 · FY2009 · RR · contact PI
Administrative Core$108,149
P01 · FY2009 · HL · contact PI
Role of Innate Immunity in Atherosclerosis$2,624,268
P01 · FY2008 · HL · contact PI
Bridge D: OXIDIZE LIPIDS IN MACROPHAGES$480,884
U54 · FY2008 · GM · contact PI
Development of a Vaccine Approach to Inhibit Atherosclerosis$386,250
R01 · FY2008 · HL · contact PI
Role of Innate Immune Mechanisms in Atherogenesis$386,250
P01 · FY2008 · HL · contact PI
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$220,273
M01 · FY2008 · RR · contact PI
Administrative Core$108,149
P01 · FY2008 · HL · contact PI
Development of a Vaccine Approach to Inhibit Atherosclerosis$386,250
R01 · FY2007 · HL · contact PI
BRIDGE D: Oxidized Lipids in Macrophages$252,695
U54 · FY2007 · GM · contact PI
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$222,097
M01 · FY2007 · RR · contact PI
SCOR in Molecular Medicine and Atherosclerosis$2,397,891
P50 · FY2006 · HL · contact PI
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$377,691
M01 · FY2006 · RR · contact PI
Immune responses to OxLDL and atherosclerosis$331,410
P50 · FY2006 · HL · contact PI
BRIDGE D: Oxidized Lipids in Macrophages$203,669
U54 · FY2006 · GM · contact PI
Core A-- Immunology$140,235
P50 · FY2006 · HL · contact PI
SCOR in Molecular Medicine and Atherosclerosis$2,126,786
P50 · FY2005 · HL
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$572,568
M01 · FY2005 · RR
Immune responses to OxLDL and atherosclerosis$324,262
P50 · FY2005 · HL
Gene transfer of recombinant antibody proteins$290,237
P01 · FY2005 · HL
BRIDGE D: Oxidized Lipids in Macrophages$196,000
U54 · FY2005 · GM
Core A-- Immunology$137,110
P50 · FY2005 · HL
SCOR in Molecular Medicine and Atherosclerosis$2,072,642
P50 · FY2004 · HL
Evaluation of Patients with Hyperlipidemia$539,340
M01 · FY2004 · RR
Anticardiolipin Antibodies and Oxidized Phospholipids$423,670
R01 · FY2004 · HL
Role of B-1 Lymphocytes in Athergenesis$380,000
R01 · FY2004 · HL
Immune responses to OxLDL and atherosclerosis$317,323
P50 · FY2004 · HL
Core A-- Immunology$134,075
P50 · FY2004 · HL
Core D-- Administrative Core$102,895
P50 · FY2004 · HL
BRIDGE D: Oxidized Lipids in Macrophages$1
U54 · FY2004 · GM
SCOR in Molecular Medicine and Atherosclerosis$2,020,076
P50 · FY2003 · HL
Anticardiolipin Antibodies and Oxidized Phospholipids$411,520
R01 · FY2003 · HL
Role of B-1 Lymphocytes in Athergenesis$380,000
R01 · FY2003 · HL
CORE--IMMUNOLOGY$131,130
P50 · FY2003 · HL
BRIDGE D: Oxidized Lipids in Macrophages$1
U54 · FY2003 · GM
SCOR in Molecular Medicine and Atherosclerosis$1,994,722
P50 · FY2002 · HL
Anticardiolipin Antibodies and Oxidized Phospholipids$399,722
R01 · FY2002 · HL
Role of B-1 Lymphocytes in Athergenesis$380,000
R01 · FY2002 · HL
Immune responses to OxLDL and atherosclerosis$295,879
P50 · FY2002 · HL
Gene transfer of recombinant antibody proteins$274,916
P01 · FY2002 · HL
CORE--IMMUNOLOGY$140,945
P50 · FY2002 · HL
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2002 · RR
LOCALIZATION OF ANTIBODIES TO OXIDIZED LDL IN NORMAL &APOPTOTIC CELLS$0
P41 · FY2002 · RR
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2002 · RR
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2002 · RR
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2002 · RR
SCOR IN MOLECULAR MEDICINE AND ATHEROSCLEROSIS$1,759,843
P50 · FY2001 · HL
Anticardiolipin Antibodies and Oxidized Phospholipids$410,181
R01 · FY2001 · HL
Role of B-1 Lymphocytes in Atherogenesis$380,000
R01 · FY2001 · HL
CORE--IMMUNOLOGY$274,326
P50 · FY2001 · HL
RELATIONSHIP OF IMMUNOLGICAL RESPONSE TO MODIFIED LDL AND ATHEROSCLEROSIS$274,326
P50 · FY2001 · HL
B-LYMPHOCYTE MEDIATED IMMUNE MECHANISMS IN ATHEROGENESIS$198,292
R01 · FY2001 · HL
LOCALIZATION OF ANTIBODIES TO OXIDIZED LDL IN NORMAL &APOPTOTIC CELLS$106,600
P41 · FY2001 · RR
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2001 · RR
LOCALIZATION OF ANTIBODIES TO OXIDIZED LDL IN NORMAL &APOPTOTIC CELLS$0
P41 · FY2001 · RR
LOCALIZATION OF ANTIBODIES TO OXIDIZED LDL IN NORMAL &APOPTOTIC CELLS$0
P41 · FY2001 · RR
Gene transfer of recombinant antibody proteins$0
P01 · FY2001 · HL
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2001 · RR
SCOR IN MOLECULAR MEDICINE AND ATHEROSCLEROSIS$1,714,961
P50 · FY2000 · HL
ANTICARDIOLIPIN ANTIBODIES AND OXIDIZED PHOSPHOLIPIDS$360,951
R01 · FY2000 · HL
B-LYMPHOCYTE MEDIATED IMMUNE MECHANISMS IN ATHEROGENESIS$300,271
R01 · FY2000 · HL
CORE--IMMUNOLOGY$185,823
P50 · FY2000 · HL
RELATIONSHIP OF IMMUNOLGICAL RESPONSE TO MODIFIED LDL AND ATHEROSCLEROSIS$185,823
P50 · FY2000 · HL
LOCALIZATION OF ANTIBODIES TO OXIDIZED LDL IN NORMAL &APOPTOTIC CELLS$38,473
P41 · FY2000 · RR
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2000 · RR
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2000 · RR
EVALUATION OF PATIENTS WITH HYPERLIPIDEMIA$0
M01 · FY2000 · RR